Checkpoint Capital’s aTyr Pharma ATYR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-432,561
Closed -$1.57M 21
2024
Q4
$1.57M Sell
432,561
-1,303,916
-75% -$3.95M 0.8% 15
2024
Q3
$3.06M Sell
1,736,477
-210,000
-11% -$382K 1.52% 10
2024
Q2
$3.04M Buy
1,946,477
+500,000
+35% +$870K 1.83% 9
2024
Q1
$2.82M Sell
1,446,477
-57,077
-4% -$99.6K 1.89% 11
2023
Q4
$2.12M Buy
+1,503,554
New +$1.93M 1.28% 13

Other funds holding ATYR

Checkpoint Capital's ATYR Position: Q1 2025 in Review

Checkpoint Capital sold out of aTyr Pharma (ATYR) in Q1 2025, closing a stake of 432,561 shares — an estimated $1.57M sold.

Checkpoint Capital first reported a position in ATYR in Q4 2023 and held it in 5 quarters. The position peaked at $3.06M in Q3 2024. 87 funds tracked by Wall St. Rank hold ATYR as of Q1 2025.

  • Checkpoint Capital reported no remaining aTyr Pharma position as of Q1 2025 after selling out during the quarter.
  • Checkpoint Capital sold 432,561 aTyr Pharma shares in Q1 2025, an estimated $1.57M.
  • Checkpoint Capital first reported a position in aTyr Pharma in Q4 2023 and held it in 5 quarters.
  • Checkpoint Capital's aTyr Pharma position peaked at $3.06M in Q3 2024.
  • 87 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2025.

Based on Checkpoint Capital's 13F filing for Q1 2025, filed 15 May 2025.